IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
Blackstone backs Pfizer obesity drug with $1.5B
Health
— 4d
Blackstone will provide up to $1.5 billion through 2028 to help Pfizer develop berobenatide, an experimental monthly GLP-1 drug for weight management and obesity-related conditions. Pfizer retains ownership and control, while Blackstone could receive milestone payments if the drug wins U.S. approval and reaches specified sales targets.
+6
+1
2
Share
Derek Foss
Pfizer keeping ownership while Blackstone waits for approval and sales milestones seems like a fair split of risk.
Study Ranks West Virginia Most Obese, South Leads
Health
— Nov 6, 2026
A WalletHub ranking finds Southern states dominate the nation’s obesity and overweight rates, with West Virginia first, followed by Mississippi, Arkansas, Louisiana and Alabama. The study links the region’s high rates to factors including unhealthy diets, limited access to nutritious food and fewer opportunities for physical activity, alongside elevated risks of chronic conditions such as diabetes and heart disease.
+2
0
Share
Lilly, Hims Partner to Offer Obesity Drugs
Business
— Nov 6, 2026
Lilly and Hims will offer Zepbound from $299/month and Foundayo from $149/month on Hims as of Nov. 6, 2026, with Hims barring compounded Lilly knockoffs.
+14
+3
3
Share
Priya Raman
Foundayo at $149 seems like the better option here if it works as well as the others.
China approves Lilly weight-loss pill, ahead of Novo
Health
— 4d
China approved Eli Lilly’s once-daily oral weight-loss drug orforglipron, making Lilly the first company with an approved GLP-1 weight-loss pill in the country and giving it an early advantage over Novo Nordisk. The pill will compete with injectable treatments from Novo, Pfizer and Innovent as demand for obesity treatments grows; Novo’s oral Wegovy is not yet approved in China.
+11
+3
2
Share
Elena Vasquez
An oral option from Lilly should help patients who prefer avoiding injections, especially as more companies race to compete.
IJR
Israel Reportedly Utilized Amazon Facial Recognition Tech To Analyze Millions Of Photos Of Palestinians
Jillian Butler · 2 min · 45m
Novo Nordisk lifts outlook on 22% obesity-sales growth
Finance
— Nov 3, 2026
Novo Nordisk raised its 2026 outlook after third-quarter revenue and adjusted operating profit beat expectations, with obesity-drug sales—particularly Wegovy—driving growth. Reported profit fell because of impairment charges, while the company said stronger GLP-1 demand underpinned its improved forecast.
+12
0
Share
Most Influential Women in World History
Yourlist
— Ranking
From ancient queens who ruled empires to modern activists who changed laws, these women left indelible marks on politics, science, and culture. Vote for who you think shaped history most profoundly.
Share
Cause of Death Revealed for Ellen Producer Matthew Wright
Ellen DeGeneres
— Nov 7, 2026
Matthew Wright, the longtime executive producer of The Ellen DeGeneres Show, died at 52 from cardiopulmonary arrest, with hypertension listed as an underlying cause and sleep apnea and obesity as contributing conditions. DeGeneres paid tribute to Wright, while a fundraiser was organized to help cover funeral and memorial costs.
+4
0
Share
Corxel, Amanat Plan $377M Obesity-Drug Merger
Business
— Oct 26, 2026
Corxel and Amanat plan a merger at a $200 million implied equity value expected to yield about $377 million in gross proceeds for oral obesity drug CX11.
+5
+2
1
Share
Sam Okafor
This deal gives the oral CX11 drug a real shot at phase 3, and 11.5 percent weight loss already looks promising for patients.
Harvard Medical School shares lessons on obesity health risks
Harvard Medical School
— Oct 21, 2026
+1
+2
1
Share
Chris Dalton
It's useful to see Harvard backing up how extra weight raises diabetes and heart risks with solid data.
Lilly’s Foundayo eases sleep apnea in two trials
Business
— Nov 6, 2026
Eli Lilly says its obesity pill Foundayo reduced obstructive sleep apnea in two late-stage trials and plans to seek U.S. approval for the use by year-end, though results suggest it may be less effective than the company’s Zepbound injection. Other potential treatments are advancing, including Pfizer’s recruiting Phase 3 trial of a monthly injection and Incannex’s oral therapy, which showed promising results in an earlier-stage study.
+6
0
Share
Daily Caller News Foundation
Key US Ally Boots Top Military Commander After Stunning Battlefield Defeat
Saudi Arabia replaced its top military commander overseeing the conflict in Yemen after Iran-backed Houthi rebels dealt the American ally a major battlefield defeat.
19m · 50 reads
Share
When you eat and sleep can matter as much as diet
Books
— Oct 21, 2026
Panda argues that syncing light, meals, sleep, and movement to the body's cellular clocks can curb obesity and metabolic disease even when calories and foods stay the same.
0
Share
ADA plans diabetes forums in Phoenix, Raleigh-Durham
Health
— Oct 26, 2026
The American Diabetes Association is holding community events in Phoenix and Raleigh-Durham to address diabetes and obesity, share evidence-based care approaches, and improve prevention and access. Separately, a World Diabetes Day webinar series will bring experts together to discuss diabetes research, prevention, and care, with this year’s campaign emphasizing early action.
+2
0
Share
Soccer vs American Football
Yourlist
— VS Battle
The world's game versus America's obsession — simplicity against spectacle.
Share
Lilly on diabetes and obesity
Health
— Sep 28, 2026
+4
0
Share
Zealand Strikes AI Obesity Drug Deal Worth $1.2B
Zealand Pharma
— Oct 13, 2026
Zealand Pharma-Generate AI obesity deal: $30M upfront to Generate, nearly $1.2B total milestones, two programs.
+5
+3
3
Share
Rachel Meyers
Only 30 million upfront for two programs feels like a bargain if Generate's technology holds up as claimed.
Jillian Michaels Faces Off With 4 Body Positivity Activists Who Object To Her Obesity Claim
Jillian Michaels
— Mar 16, 2026
Fitness expert Jillian Michaels debated four body positivity activists who disagreed with her about obesity during a Monday episode of Jubilee’s “Surrounded” series. Michaels claimed on the Jubilee episode that “Obesity…
0
Share
IJR
Spanberger Wants Power Giants To Pay Customers $6.5 Billion Before They Can Merge
Simon August · 6 min · 1h
Novo says Wegovy trial moved 40% of young children out of obesity
semaglutide
— Sep 7, 2026
In Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.
+3
+1
3
Share
Chris Dalton
Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.
The impossible would-you-rather gauntlet
Quizie
— Quiz
Eight impossible choices. The AI studies your rulings and delivers a psychological profile you didn't consent to.
Share
Novo Nordisk Rebrands as Novo While Fighting for Obesity Market Share
Novo Nordisk
— Sep 14, 2026
On Sept. 14, 2026, Novo Nordisk said it will operate as Novo; NVO fell about 2.14% that day and roughly 15% YTD, with 38.8% obesity share versus Lilly's 60.9%.
+13
+3
1
Share
Marcus Bell
Rebranding to just Novo feels like a distraction when their obesity share has already slipped to 38 percent against Lilly.
Novo Nordisk licenses potential once-weekly obesity pill from Hengrui in $2.6B deal
Novo Nordisk
— Sep 29, 2026
Novo Nordisk will pay Hengrui $300 million upfront, and up to $2.6 billion total, for HRS-1596, a GLP-1/GIP candidate aimed at once-weekly oral obesity dosing.
+11
+2
2
Share
Dana Whitfield
Spending billions on something still in trials feels like a gamble, but Novo must see real potential in that GLP-1 combo from Hengrui.
Pelosi Addresses Her ‘Morbidly Obese’ Comments About Trump: ‘I Didn’t Know He’d Be so Sensitive’
Reporting
— May 19, 2020
House Speaker Nancy Pelosi (D-Calif.) is responding to President Donald Trump’s attack on her after she called him “morbidly obese.” “I didn’t know that he would be so sensitive,” Pelosi said during an interview on…
0
Share
‘Dangerous and Reckless’: GOP Rep Kicked Out of Congress Slams ‘Glorifying Obesity’
Reporting
— Jan 16, 2024
Former Rep. George Santos (R-N.Y.) shared his journey using the weight loss drug Ozempic and slammed the “glorifying” of obesity as being “dangerous and reckless.” In a post on X, formerly Twitter, Santos shared he…
0
Share
Daily Caller News Foundation
Maria Salazar Brags About Amnesty Bill Surpassing Necessary Co-Sponsors
Republican Florida Rep. Maria Salazar sent an email Monday celebrating that her amnesty bill garnered more supporters.
25m · 8 reads
Share
Unfit to Serve? Obesity Epidemic Creating Recruitment Woes, National Security Risk – Biden’s DEI Policies Don’t Help
Opinion
— Sep 3, 2023
The U.S. military has faced a number of problems recently in recruiting new soldiers, especially in a nation with an increasing obesity problem among its young people. But President Joe Biden’s obsession with pushing…
0
Share
Modern comfort stripped away the struggle our bodies still need
Books
— Oct 17, 2026
Easter links rising obesity, anxiety, and chronic disease to lives that erased cold, hunger, loaded walking, and boredom.
0
Share
Oval Office Scare: Guest Collapses During Trump Obesity-Drug Event, Rushed by Dr. Oz
Donald John Trump
— Nov 7, 2025
A White House press event took a frightening turn Thursday afternoon when a guest collapsed in the Oval Office during an obesity-drug announcement. According to the New York Post , President Donald Trump and Dr. Mehmet…
0
Share
China obesity rate expected above 65% by 2030
People's Republic of China
— Aug 24, 2026
China’s National Health Commission suggests obesity could exceed 65% of the population by 2030, triggering a push by major drugmakers to promote GLP-1 weight-loss injections through indirect public advertising in places like metro stations and stadiums due to bans on direct prescription-drug ads. Companies including Novo Nordisk, Lilly, Pfizer, and Innovent Biologics are vying for market share, with Lilly leading online sales on Alibaba/JD.com and campaigns emphasizing obesity risks and related conditions such as sleep apnea without naming products.
+2
0
Share
England's young women face Type 2 diabetes surge
Health
— Jul 21, 2026
A Lancet study and Imperial College London analysis show a sharp rise in early-onset type 2 diabetes in England, especially among women under 40 and those aged 20-29, linked to rising obesity. While diagnoses in older adults decline, experts warn the trend carries greater health risks and call for earlier, more intensive obesity and lifestyle interventions.
+4
0
Share
IJR
Lutnick Caught In Bipartisan Crossfire Over Chinese Spy Scandal Rocking Nvidia
Dylan Kresak · 4 min · 1h
Load more